Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
MAM-E17 rat model impairments on a novel continuous performance task: effects of potential cognitive enhancing drugs
NYU Med Ctr, Neurosci Inst, New York, NY 10016 USA.;NYU Med Ctr, Dept Neurosci & Physiol, New York, NY 10016 USA.;Univ Cambridge, Dept Psychol, Cambridge, England.;Univ Cambridge, MRC, Cambridge, England.;Univ Cambridge, Wellcome Trust Behav & Clin Neurosci Inst, Cambridge, England..
NYU Med Ctr, Neurosci Inst, New York, NY 10016 USA.;NYU Med Ctr, Dept Neurosci & Physiol, New York, NY 10016 USA.;Univ Cambridge, Dept Psychol, Cambridge, England.;Univ Cambridge, MRC, Cambridge, England.;Univ Cambridge, Wellcome Trust Behav & Clin Neurosci Inst, Cambridge, England..
NYU Med Ctr, Neurosci Inst, New York, NY 10016 USA.;NYU Med Ctr, Dept Neurosci & Physiol, New York, NY 10016 USA.;Univ Cambridge, Dept Psychol, Cambridge, England.;Univ Cambridge, MRC, Cambridge, England.;Univ Cambridge, Wellcome Trust Behav & Clin Neurosci Inst, Cambridge, England..
Univ Cambridge, Dept Psychol, Cambridge, England.;Univ Cambridge, MRC, Cambridge, England.;Univ Cambridge, Wellcome Trust Behav & Clin Neurosci Inst, Cambridge, England.;Beijing Int Studies Univ, Dept Hlth Ind Management, 1 Dingfuzhuang Nanli, Beijing, Peoples R China..
Show others and affiliations
2017 (English)In: Psychopharmacology, ISSN 0033-3158, E-ISSN 1432-2072, Vol. 234, no 19, p. 2837-2857Article in journal (Refereed) Published
Abstract [en]

Impairments in attention and inhibitory control are endophenotypic markers of neuropsychiatric disorders such as schizophrenia and represent key targets for therapeutic management. Robust preclinical models and assays sensitive to clinically relevant treatments are crucial for improving cognitive enhancement strategies. We assessed a rodent model with neural and behavioral features relevant to schizophrenia (gestational day 17 methylazoxymethanol acetate treatment (MAM-E17)) on a novel test of attention and executive function, and examined the impact of putative nootropic drugs. MAM-E17 and sham control rats were trained on a novel touchscreen-based rodent continuous performance test (rCPT) designed to closely mimic the human CPT paradigm. Performance following acute, systemic treatment with an array of pharmacological compounds was investigated. Two cohorts of MAM-E17 rats were impaired on rCPT performance including deficits in sensitivity (d') and increased false alarm rates (FARs). Sulpiride (0-30 mg/kg) dose-dependently reduced elevated FAR in MAM-E17 rats whereas low-dose modafinil (8 mg/kg) only improved d' in sham controls. ABT-594 (5.9-19.4 mu g/kg) and modafinil (64 mg/kg) showed expected stimulant-like effects, while LSN2463359 (5 mg/kg), RO493858 (10 mg/kg), atomoxetine (0.3-1 mg/kg), and sulpiride (30 mg/kg) showed expected suppressant effects on performance across all animals. Donepezil (0.1-1 mg/kg) showed near-significant enhancements in d', and EVP-6124 (0.3-3 mg/kg) exerted no effects in the rCPT paradigm. The MAM-E17 model exhibits robust and replicable impairments in rCPT performance that resemble attention and inhibitory control deficits seen in schizophrenia. Pharmacological profiles were highly consistent with known drug effects on cognition in preclinical and clinical studies. The rCPT is a sensitive and reliable tool with high translational potential for understanding the etiology and treatment of disorders affecting attention and executive dysfunction.

Place, publisher, year, edition, pages
SPRINGER , 2017. Vol. 234, no 19, p. 2837-2857
Keywords [en]
Attention, MAM-E17, Executive function, Touch screen, Behavioral pharmacology, Schizophrenia, ADHD, Animal model
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-334738DOI: 10.1007/s00213-017-4679-5ISI: 000409895900001PubMedID: 28744563OAI: oai:DiVA.org:uu-334738DiVA, id: diva2:1161044
Funder
EU, FP7, Seventh Framework ProgrammeWellcome trustSwedish Research Council, 350-2012-230Available from: 2017-11-29 Created: 2017-11-29 Last updated: 2018-01-13Bibliographically approved

Open Access in DiVA

fulltext(2425 kB)18 downloads
File information
File name FULLTEXT01.pdfFile size 2425 kBChecksum SHA-512
9631435283df07e628085415b8f51ee13c7ee11b72fedb51b1ec5eb6afccad7dee029fff002e0e33d97ddb54e2bfe205667c16ebddda385e61fb3e81009f5e08
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Alsiö, Johan
By organisation
Department of Neuroscience
In the same journal
Psychopharmacology
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 18 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 114 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf